What is Videregen?
Videregen is at the forefront of tissue repair, specializing in the application of thymus stem cell science to combat diseases linked to thymus dysfunction, aging, and autoimmunity. The company's innovative BioThymus technology platform is engineered to rejuvenate thymus function, thereby enhancing T cell development. This advancement holds the potential to treat conditions such as athymia and improve transplant tolerance. Videregen's strategic focus on the medical and healthcare sectors, particularly in immunology and regenerative medicine, positions it to address age-related immune deterioration and potentially reverse age-related pathologies.
How much funding has Videregen raised?
Videregen has raised a total of $6.4M across 3 funding rounds:
Multiple Rounds
$6.4M
Private Equity (2014): $2M with participation from North West Fund
Grant (2014): $4M led by North West Fund for Biomedical
Angel/Seed (2014): $481K supported by London Business Angel
Key Investors in Videregen
North West Fund
The North West Fund is a significant investment vehicle focused on providing debt and equity funding to SMEs in the North West of England, aiming to foster long-term growth and prosperity within the region.
North West Fund for Biomedical
The North West Fund is a significant investment vehicle focused on providing debt and equity funding to SMEs in the North West of England, aiming to foster long-term growth and prosperity within the region.
London Business Angel
London Business Angel is an investment entity that supports early-stage companies, likely focusing on innovative ventures within the London ecosystem.
What's next for Videregen?
The recent major strategic investment signifies a pivotal moment for Videregen, likely enabling the company to accelerate its research and development pipeline, scale its proprietary BioThymus technology, and expand its market reach within the immunology and regenerative medicine fields. This capital will be instrumental in advancing clinical trials and solidifying its position as a leader in thymus-based therapies.
See full Videregen company page
